Freeline Reports Full Year 2021 Financial Results and Business Highlights
31 mars 2022 16h01 HE
|
Freeline Therapeutics
Phase 1/2 programs on track in Hemophilia B and Gaucher disease and accelerated in Fabry disease Extended financial runway and streamlined organization support Companythrough key data readouts across...
Freeline Announces Updated Development Plan and Timelines for FLT190 for People with Fabry Disease
24 mars 2022 07h00 HE
|
Freeline Therapeutics
Company to progress to second dose cohort in the MARVEL-1 study immediately, with first patient dosing expected in mid-2022 LONDON, March 24, 2022 (GLOBE NEWSWIRE) -- Freeline...
Freeline to Participate in Upcoming Investor Conferences
23 mars 2022 07h00 HE
|
Freeline Therapeutics
LONDON, March 23, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that senior management will participate in the following...
Freeline Closes $26.1 Million Registered Direct Offering of American Depositary Shares
15 mars 2022 16h05 HE
|
Freeline Therapeutics
LONDON, March 15, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), today announced the closing of the registered direct offering of its...
Freeline Announces $26.1 Million Registered Direct Offering of American Depositary Shares
10 mars 2022 21h16 HE
|
Freeline Therapeutics
LONDON, March 11, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...
Freeline Announces First Patient Dosed in the Phase 1/2 B-LIEVE Dose-Confirmation Trial in Hemophilia B
09 mars 2022 07h44 HE
|
Freeline Therapeutics
On track to complete dosing of the first cohort and share initial data by the end of the first half of 2022 On track to start pivotal Phase 3 trial in 2023 LONDON, March 09, 2022 (GLOBE NEWSWIRE)...
Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 mars 2022 16h01 HE
|
Freeline Therapeutics
LONDON, March 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that on February 28, 2022, the Company granted three newly...
Freeline Presents on Its Fabry and Gaucher Disease AAV-Based Gene Therapies at the 18th Annual WORLDSymposium™
08 févr. 2022 07h00 HE
|
Freeline Therapeutics
FLT190 well-tolerated with promising early efficacy in Fabry disease including sustained α-Gal A expression up to two years GALILEO-1, a first-in-human, open-label, international, multicenter Phase...
Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 févr. 2022 16h01 HE
|
Freeline Therapeutics
LONDON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...
Freeline Appoints Henning R. Stennicke, PhD, as Chief Scientific Officer to Lead Research and Discovery
03 févr. 2022 07h00 HE
|
Freeline Therapeutics
LONDON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...